Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 308

Results For "ABLE"

4960 News Found

FDA approval of deep brain stimulators will drive APAC market, says GlobalData
News | July 24, 2022

FDA approval of deep brain stimulators will drive APAC market, says GlobalData

Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression


Import of Medical Devices Up by Record 41% in FY22: AiMeD
News | July 24, 2022

Import of Medical Devices Up by Record 41% in FY22: AiMeD

India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21


Merck opens microbiology application lab in Jigani, Bengaluru
Diagnostic Center | July 24, 2022

Merck opens microbiology application lab in Jigani, Bengaluru

Merck’s first microbiology application and training lab in India


Dr. Reddy's announces the first-to-market, OTC launch of Allegra-D in the US market
Drug Approval | July 24, 2022

Dr. Reddy's announces the first-to-market, OTC launch of Allegra-D in the US market

Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.


Syngene reports revenue from operations up 8% in Q1 FY 23
News | July 21, 2022

Syngene reports revenue from operations up 8% in Q1 FY 23

Company raises the annual revenue guidance from mid-teens to high teens


India’s first 4th Gen transcatheter mitral valve performed at Apollo Chennai
News | July 21, 2022

India’s first 4th Gen transcatheter mitral valve performed at Apollo Chennai

Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs


Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus
News | July 20, 2022

Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.


Essential Pharma progress in its ESG performance
Sustainability | July 20, 2022

Essential Pharma progress in its ESG performance

The company now exceeds the sector benchmark for its overall ESG rating and for all three measures


Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy
Drug Approval | July 20, 2022

Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China